Ridaforolimus (Deforolimus, AP23573, MK-8669)
Ridaforolimus Specification
Appearance | Off-white Crystalline powder | Standard Packing | 500mg/bag or per customer request | |
Purity (HPLC) | 95% | Inventory | Normally we have Ridaforolimus in stock | |
Melting point | 95-98 °C (lit.) | |||
Ridaforolimus physical parameters | ||||
CAS No: | 572924-54-0 | |||
Formula | C53H84NO14P | |||
Molecular Weight | 990.21 | |||
Synonym | AP23573; MK-8669 | |||
Solubility | Soluble in DMSO, Methanol | |||
Structure | ![]() |
|||
Certificate of Analysis | Ridaforolimus (Deforolimus, AP23573, MK-8669) COA | |||
Literature | Ridaforolimus (Deforolimus, AP23573, MK-8669) literature | |||
MSDS | Ridaforolimus (Deforolimus, AP23573, MK-8669) MSDS | |||
References: | ||||
1. | J. Nemunaitis et al: Clinical Oncology 25(6) 2013, 336–342. Oral ridaforolimus (40 mg QDx5/wk) is feasible to combine with standard doses of bevacizumab, although careful patient selection would be needed to mitigate the risk of bowel perforation-related adverse events. Combination therapy produced prolonged stable disease in several heavily pretreated patients. | |||
2. | Christine M. Hartford et al: Clin Cancer Res 2009;15(4) Deforolimus was well tolerated on the schedule tested in this trial with toxicity and pharmacokinetic profiles that were similar to that of other mTOR inhibitors. Additional phase II studies are needed to determine if deforolimus is superior to other mTOR inhibitors in terms of efficacy. The change in serum cholesterol as a potential biomarker of activity should be studied further. Full text | |||
. | ||||
Copyright © 2020 - . All Rights Reserved |